

<i>Short Name</i>	<i>Comments</i>	<i>Type</i>	<i>Investigator</i>	<i>Contact</i>
<b><i>Disease site specific</i></b>				
<b><i>Treatment</i></b>				
A021501	Preoperative Extended Chemotherapy VS Chermotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EA2142	GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMAS: Advanced G3 Non-Small Cell: Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
RTOG 0848	HEAD OF PANCREAS ADENOCARCINOMA/RESECTED: A Phase II-R and A Phase III Trial Evaluating Both *Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment Phase II is Closed <a href="#">For More Information</a>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
HAI for Pancreatic Mets	A Phase II Trial of Hepatic Artery Infusional Floxuridine with Systemic Chemotherapy in the Treatment of Pancreatic Cancer Liver Metastases <a href="#">For More Information</a>	Treatment	<a href="#">Dr. Paul Wright</a>	Marianne Morrissey <a href="mailto:marianne.morrissey@spectrumhealth.org">marianne.morrissey@spectrumhealth.org</a> (616) 391-1129
<b><i>Protocols that are NOT disease site specific</i></b>				
<b><i>Treatment</i></b>				
Alexion ALXN6000-ONC-102	Alexion Protocol ALXN6000-ONC-102: A Multicenter, Dose-Escalation, Phase 1 Study of Samalizumab (ALXN6000) to Evaluate the Pharmacokinetics, Safety, and Tolerability in Patients with Advanced Cancer	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
	A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-115 in Patients with Advanced Solid Tumors or Lymphomas	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554

	<b>A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of intravenously Administered APG-1252 in Patients with Small Cell Lung Cancer (SCLC) and Other Solid Tumors</b>	Treatment	<a href="#">START</a> <a href="#">Midwest</a> <a href="#">Investigators</a>	START Midwest (616) 954-5554
	<b>A First-in-Human Phase 1, Dose Escalation, Safety and Pharmacokinetic Study of PF-06647020 in Adult Patients with Advanced Solid Tumors</b>	Treatment	<a href="#">START</a> <a href="#">Midwest</a> <a href="#">Investigators</a>	START Midwest (616) 954-5554
	<b>A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity</b>	Treatment	<a href="#">START</a> <a href="#">Midwest</a> <a href="#">Investigators</a>	START Midwest (616) 954-5554
	<b>A Phase 1a/2a Cohort Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID100, an Anti-Human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Linked to the Maytansinoid DM1, in Patients with Advanced or Metastatic Solid Tumors of Epithelial Origin</b>	Treatment	<a href="#">START</a> <a href="#">Midwest</a> <a href="#">Investigators</a>	START Midwest (616) 954-5554
<b>BGB-290</b>	<b>A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors</b>	Treatment	<a href="#">START</a> <a href="#">Midwest</a> <a href="#">Investigators</a>	START Midwest (616) 954-5554
<b>ALEXO AT148001</b>	<b>Alexo Protocol AT148001: A Phase 1, Dose Escalation Study of ALX148 in Patients with Advanced Solid Tumors and Lymphoma</b>	Treatment	<a href="#">START</a> <a href="#">Midwest</a> <a href="#">Investigators</a>	START Midwest (616) 954-5554
	<b>A First-in-Human Phase 1, Dose Escalation, Safety and Pharmacokinetic Study of PF-06647020 in Adult Patients with Advanced Solid Tumors</b>	Treatment	<a href="#">START</a> <a href="#">Midwest</a> <a href="#">Investigators</a>	START Midwest (616) 954-5554

<b>SCI-CD47-001</b>	<b>First-in-Human Phase I Dose Escalation Trial of HU5F9-G4 in Patients with Advanced Solid Malignancies</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>ASN002</b>	<b>A Phase I/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ASN002 in Relapsed/Refractory Lymphoma and Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>20150195 AMG 820</b>	<b>A Phase Ib/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination with Pembrolizumab in Select Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>R3767-ONC-1613</b>	<b>A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1-mAb) in Patients with Advanced Malignancies</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>CP-MGA012-01</b>	<b>A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>MK-4820</b>	<b>A Phase 1 Trial of MK-4820 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>MK-4280-001</b>	<b>A Phase Ib/II Study to Evaluate the Safety and Tolerability of Preladenant as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Malignancies</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554

<b>LZM009-001</b>	<b>A First-in-Human, Multicenter, Open-label, Phase 1 Dose Escalation Study of LZM009 in Subjects with Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>ASN003-101</b>	<b>A Phase I, Open-Label, Dose-Finding and Cohort Expansion Study of ASN003 in Subjects with Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>MK-8353-013</b>	<b>A Phase 1b Study to Evaluate the Safety and Tolerability of MK-8353 in Combination with Pembrolizumab in Patients with Advanced Malignancies</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>5F9004</b>	<b>A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>CP-MGA012-01</b>	<b>A Phase 1 Study of the Safety, tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>CVM-001</b>	<b>A Phase I Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients with Advanced Cancer</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>APX_CLN_0011</b>	<b>A Phase 1 Study of APX3330 in Patients with Advanced Solid Tumors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554
<b>CPI-1205-202</b>	<b>A Phase 1 Study of CPI-1205 with Ipilimumab or Pembrolizumab in Patients with Advanced Solid Tumors Followed by a Phase 2 Basket Study of CPI-1205 with Ipilimumab or Pembrolizumab in Selected Tumor Types Previously Treated with PD-1 or PD-L1 Inhibitors</b>	Treatment	<a href="#">START Midwest Investigators</a>	START Midwest (616) 954-5554

<b>NRG CC003</b>	<b>Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer</b>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
<b>NRG CC001</b>	<b>A Randomized Phase III Trial of Memantine and Whole Brain Radiotherapy With or Without Hippocampal Avoidance in Patients with Brain Metastases</b>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
<b>A071401</b>	<b>Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations</b>	Treatment	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
<b><i>Molecular Profiling</i></b>				
<b>QOL Multisite EAQ-152</b>	<b>EAQ-152 - (COMET MATCH) - A randomized Study of Pre-disclosure Genetic Education v Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
<b>EAY131 - MATCH</b>	<b>MOLECULAR ANALYSIS / ADVANCED REFRACTORY SOLID TUMORS OR LYMPHOMAS; Targeted Therapy Directed by Genetic Testing – See sub-protocols below</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
<b>EAY131</b>	<b>Dasatinib in Patients with Tumors with DDR2 Mutations</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			

EAY131 - A	<b>Solid Tumors (Other than SC &amp; NSCLC) or Lymphomas; <i>Afatinib</i> in Patients that have Activating Mutations of EGFR and Have Progressed After Standard Treatment</b> <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EAY131 - B	<b>Tumors with HER2 Activating Mutations; Treatment: <i>Afatinib</i></b>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EAY131 - C1	<b><i>Crizotinib</i> in Patients with Tumors with MET Amplification</b>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EAY131 - C2	<b><i>Crizotinib</i> in Patients with Tumors with MET Exon 14 Deletion</b>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EAY131 - E	<b>Tumors Having EGFR T790M Mutations (Except NSCLC) or Rare Activating Mutations of EGFR; Treatment: <i>AZD9291</i></b>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EAY131 - F	<b>Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Translocations; Treatment: <i>Crizotinib</i></b>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EAY131 - G	<b>ROS1 Translocations (Other Than Patients with NSCLC); Treatment: <i>Crizotinib</i></b>  <a href="#">For More Information</a>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>

EAY131 - H	<b>Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer); Treatment: <u>Dabrafenib</u> and <u>Trametinib</u></b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - J	<b><u>Trametinib</u> and <u>Pertuzumab</u> (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - L	<b>Phase II Study of MLN0128 (<u>TAK-228</u>) in Patients with Tumors with mTOR Mutations</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - M	<b>Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - R	<b>BRAF Fusions, or Non-V600E, Non-V600K BRAF Mutations; Treatment: <u>Trametinib</u></b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - S1	<b><u>Trametinib</u> in Patients with Tumors with NF1 Mutations</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - S2	<b><u>Trametinib</u> in Patients with Tumors with GNAQ or GNA 11 Mutations</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			

EAY131 - T	<b>Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations; Treatment: <u><i>GDC-0449 (vismodegib)</i></u></b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - V	<b>Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) Treatment: <u><i>Sunitinib</i></u></b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - W	<b>Phase II Study of <u><i>AZD4547</i></u> in Patients with Tumors with Aberrations in the FGFR Pathway</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - X	<b><u><i>Dasatinib</i></u> in Patients with Tumors with DDR2 Mutations</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - Y	<b><u><i>AZD5363</i></u> in Patients with Tumors with AKT Mutations</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - Z1A	<b><u><i>Binimetinib</i></u> in Patients with Tumors (Other than Melanoma) with NRAS Mutations</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - Z1B	<b>MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC</b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			



EAY131 - Z1D	<b><i>Nivolumab</i></b> in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - Z1E	<b>Testing <i>LOXO-101</i> as Potentially Targeted Treatment in Cancers with NTRK Genetic Changes</b>		<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
EAY131 - Z1I	<b>Testing <i>AZD1775</i> as a Possible Treatment in People who have Cancer with BRCA Mutations</b>		<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
ASCO TAPUR	<b>Targeted Agent and Profiling Utilization Registry Study. <i>All drugs provided</i></b>	Molecular Profiling	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			

<i>Biorepository</i>				
NCI PDM 9846	<b>Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)</b>	Biobanking	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
SHARE	<b>The Spectrum Health Universal Biorepository Provides a Robust, Diverse Offering of High, Quality Research and Potential Diagnostic Samples Associated with Relevant De-identified Clinical Data to Investigators</b>	Biobanking	Cottingham, Sandra	Spectrum Health Biorepository <a href="mailto:david.chesla@spectrumhealth.org">david.chesla@spectrumhealth.org</a> (616) 267-2629
	<i>This study will collect high-quality biologic specimens including tumor/diseased tissue, matched normal tissue, bodily fluids, and correlating health information from patients with the diagnosis of neoplasm or other conditions and related data for use in laboratory research.</i>			<a href="mailto:david.chesla@spectrumhealth.org">david.chesla@spectrumhealth.org</a> (616) 267-2629
<i>Assessment/ Education</i>				
URCC 13059 GAP-70	<b>Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy for Advanced Cancer: Reducing Chemotherapy Toxicity in Older Adults</b>	Other	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
<i>Symptom Management</i>				
S1415CD	<b>A Pragmatic Trial To Evaluate a Guideline Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)</b>	Symptom Management	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			
URCC 04040 YOCAS	<b>A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors</b>	Symptom Management	<a href="#">CRCWM Physician Investigators</a>	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
	<a href="#">For More Information</a>			

---

**URCC 16070**      **Treatment of Refractory Nausea**

Symptom      [CRCWM](#)      CRCWM  
Management      [Physician](#)      (616) 391-1230  
                                 [Investigators](#)      [www.crcwm.org](http://www.crcwm.org)

[For More Information](#)